Abstract
To examine the effects of telmisartan on peroxisome proliferator–activated receptor γ activation, we compared the effects of telmisartan with those of candesartan on adipocytokines and glucose and lipid metabolism in vivo and in vitro. In vivo, 56 patients with both type 2 diabetes and hypertension were enrolled and randomized to receive either telmisartan (40 mg) or candesartan (8 mg) for 3 months. Serum adiponectin, HbA1c levels, lipid profiles and blood pressure were recorded at the beginning and 3 months later. In vitro, differentiated 3T3-L1 adipocytes were treated with telmisartan, candesartan, pioglitazone or vehicle for 24 h, and then adiponectin mRNA and protein levels were measured. The results showed that most of the metabolic parameters, including the lipid profiles, did not change significantly during the study in either group. However, the changes in serum adiponectin and plasma glucose over 3 months were significantly greater in the telmisartan group than in the candesartan group. In vitro, although the protein level of adiponectin was not significantly elevated, the mRNA expression of adiponectin was elevated 1.5-fold by telmisartan in 3T3-L1 adipocytes. Our findings suggest that telmisartan may have beneficial effects in type 2 diabetes beyond its antihypertensive effect.
Similar content being viewed by others
Article PDF
References
Dahlof B, Devereux RB, Kjeldsen SE, et al: Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
Pfeffer MA, Swedberg K, Granger CB, et al: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–766.
Julius S, Kjeldsen SE, Weber M, et al: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 2004; 363: 2022–2031.
Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G : Effects of an angiotensin-converting–enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.
DREAM Trial Investigators, Bosch J, Yusuf S, et al: Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551–1562.
DREAM Trial Investigators, Gerstein HC, Yusuf S, Bosch J, et al: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096–1105.
Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR gamma–modulating activity. Hypertension 2004; 43: 993–1002.
Schupp M, Clemenz M, Gineste R, et al: Molecular characterization of new selective proxisome proliferator–activated receptor gamma modulators with angiotesin receptor blocking activity. Diabetes 2005; 54: 3442–3452.
Hara K, Horikoshi M, Yamauchi T, et al: Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 2006; 29: 1357–1362.
Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT : Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes 2006; 55: 249–259.
Marshall TG, Lee RE, Marshall FE : Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 2006; 3: 1.
Arita Y, Kihara S, Ouchi N, et al: Paradoxial decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 1999; 257: 79–83.
Wang P, Keijer J, Bunschoten A, Bouwman F, Renes J, Mariman E : Insulin modulates the secretion of proteins from mature 3T3–L1 adipocytes: a role for transcriptional regulation of processing. Diabetologia 2006; 49: 2453–2462.
Bogan JS, Lodisch HF : Two compartments for insulin-stimulated exocytosis in 3T3–L1 adipocytes defined by endogenous ACRP30 and GLUT4. J Cell Biol 1999; 146: 609–620.
Tamori Y, Masugi J, Nishino N, et al: Role of peroxisome proliferator–activated receptor-gamma in maintenance of the characteristics of mature 3T3–L1 adipocytes. Diabetes 2002; 51: 2045–2055.
Schupp M, Janke J, Clase R, Unger T, Kintscher U : Angiotensin type 1 receptor blockers induce peroxisome proliferator–activated receptor-gamma activity. Circulation 2004; 109: 2054–2057.
Li M, Li W, Kim HJ, et al: Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR. J Surg Res 2004; 119: 130–137.
Ouchi N, Kihara S, Funahashi T, et al: Reciprocal association of C-reactive protein in blood stream and adipose tissue. Circulation 2003; 107: 671–674.
Nomura S, Shouzu A, Omoto S, et al: Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006; 117: 385–392.
Furuhashi M, Ura N, Higashiura K, et al: Blockade of the renin-angiotensin system increases adiponectin concentration in patients with essential hypertension. Hypertension 2003; 42: 76–81.
Clasen R, Schupp M, Foryst-Ludwig A, et al: PPAR gamma activating angiotensin type 1 receptor blockers induce adiponectin. Hypertension 2005; 46: 137–143.
Miura Y, Yamamoto N, Tsunekawa S, et al: Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28: 757–758.
Pershadsingh HA, Kurtz TW : Insulin-sensitizing effects of telmisartan: implications for treating insulin-resistant hypertension and cardiovascular disease. Diabets Care 2004; 27: 1015.
Mori Y, Itho Y, Tajima N : Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. Adv Ther 2007; 24: 146–153.
Benndorf RA, Rudolph T, Appel D, et al: Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension. Metabolism 2006; 55: 1159–1164.
Nagel JM, Tietz AB, Goeke B, Parhofer KG : The effect of telmisartan on glucose and lipid metabolism in nondiabetic, insulin-resistant subjects. Metabolism 2006; 55: 1149–1154.
Vitale C, Mercuro G, Castiglioni C, et al: Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome. Cardiovasc Diabetol 2005; 4: 6.
Negro R, Formoso G, Hassan H : The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients. J Endocrinol Invest 2006; 29: 957–961.
Derosa G, Fogari E, D'Angelo A, et al: Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone. J Clin Pharm Ther 2007; 32: 261–268.
Fujimoto M, Masuzaki H, Tanaka T, et al: An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3–L1 adipocytes. FEBS Lett 2004; 576: 492–497.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamada, S., Ano, N., Toda, K. et al. Telmisartan but Not Candesartan Affects Adiponectin Expression In Vivo and In Vitro. Hypertens Res 31, 601–606 (2008). https://doi.org/10.1291/hypres.31.601
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.601
Keywords
This article is cited by
-
Hypoadiponectinemia and aldosterone excess are associated with lack of blood pressure control in subjects with resistant hypertension
Hypertension Research (2013)
-
Telmisartan at 80 mg/Day Increases High-Molecular-Weight Adiponectin Levels and Improves Insulin Resistance in Diabetic Patients
Advances in Therapy (2012)
-
A small difference in the molecular structure of angiotensin II receptor blockers induces AT1 receptor-dependent and -independent beneficial effects
Hypertension Research (2010)
-
Do angiotensin II type 1 receptor blockers have molecular effects?
Hypertension Research (2010)
-
Production and Secretion of Adiponectin from 3T3-L1 Adipocytes: Comparison of Antihypertensive Drugs
American Journal of Hypertension (2009)